COMBI-AD (NCT01682083) evaluated dabrafenib plus trametinib for patients with BRAF-mutated AJCC-stage III melanoma, and here the final results for RFS, distant-metastasis-free survival and overall survival are presented.
Axel Hauschild, MD, PhD, University Hospital Schleswig-Holstein
Advertisement
Articles by Axel Hauschild, MD, PhD, University Hospital Schleswig-Holstein
PIVOTAL (NCT02938299) is an open label, randomized, multicenter, phase 3 trial evaluating Daromun as a neoadjuvant intralesional therapy for resectable, locally advanced Stage III melanoma.
Advertisement
Latest Updated Articles
Molecular Testing in Metastatic MelanomaPublished: January 22nd 2021 | Updated:
The Role of COVID-19 in Adjuvant Treatment Decisions in MelanomaPublished: January 22nd 2021 | Updated:
Looking at Approved Agents in Metastatic MelanomaPublished: January 29th 2021 | Updated:
Testing and BRAF Mutations in MelanomaPublished: January 8th 2021 | Updated:
Future Directions in Metastatic MelanomaPublished: February 5th 2021 | Updated:
A Look at the KEYNOTE-054 and COMBI-AD DataPublished: January 15th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
3
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5